Reviva Pharmaceuticals Holdings, Inc. Warrants (RVPHW)

• Market cap: $3.34M
• 1 day: 8.16%
• 5 days: 47.02%
• 1 month: 12.76%
• 3 months: -46.69%
• 6 months: -65.90%
• Year to date: -73.48%
• 1 year: -76.13%
• 5 years: -65.89%
• 10 years: -80.11%
• Sector: Healthcare
• Industry: Biotechnology

About: Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Employees: 14

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

59% more capital invested

Capital invested by funds: $628 [Q4 2024] → $1K (+$372) [Q1 2025]

0.04% more ownership

Funds ownership: 0.01% [Q4 2024] → 0.05% (+0.04%) [Q1 2025]

50% less funds holding

Funds holding: 2 [Q4 2024] → 1 (-1) [Q1 2025]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2